Neuronavigation-guided Focused Ultrasound-induced Blood-brain Barrier Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a single-element transducer with neuronavigation guidance. Preliminary results from our phase 1a study demonstrate that our neuronavigation-guided FUS system was capable of safely and transiently open the BBB in participants with AD. The information collected in this new study may be used to design future clinical trials to ultimately provide a viable alternative for treatment of AD in a safe and noninvasive manner.
Our secondary objective includes the assessment of the therapeutic efficacy of FUS-BBBO in reducing amyloid beta and neurofibrillary tangles, the main hallmark pathologies of AD, using PET tracers. Based on our preclinical studies in AD transgenic mouse models, FUS-BBBO alone was able to reduce both the amyloid beta and tau protein load, resulting in improvements in behavioral tasks assessing memory. Therefore, in this new study, the effect of FUS-BBBO on the amyloid beta and tau protein load in patients with AD will be assessed through the use of PET tracers.

Start Date01 Aug 2026

Sponsor / Collaborator-

NCT06790394

/ Not yet recruitingPhase 1

A Test-retest Study to Evaluate the Reproducibility of [18F]Florbetaben PET Imaging in Patients With Cardiac Amyloidosis and Control Patients

This study is an open-label study to evaluate and characterize test-retest reliability of [18F]florbetaben PET in subjects with AL-CA and ATTR-CA compared to non-CA subjects. Quantification of the [18F]florbetaben parameters related to the deposition of amyloid in the heart (such as Myocardial Tracer Retention (MTR) or Retention Index (RI)), and the variability in these parameters after repeated imaging will be evaluated. Measurement of blood metabolites and comparison of invasive with non-invasive quantification of [18F]florbetaben uptake in the heart will be performed.

Start Date01 Oct 2025

Sponsor / Collaborator

Life Molecular Imaging Ltd.

[+1]

NCT07012993

/ RecruitingPhase 2IIT

Evaluation of Ultralow Dose PET Imaging for Detecting Amyloid Tracer Uptake

The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and monitoring. The main question it aims to answer is:
Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-Florbetapir or 18F-Flutemetamol and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours

Start Date20 May 2025

Sponsor / Collaborator

Nuclear Energy Institute

100 Clinical Results associated with Florbetapir F-18

100 Translational Medicine associated with Florbetapir F-18

100 Patents (Medical) associated with Florbetapir F-18

384

Literatures (Medical) associated with Florbetapir F-18

01 Oct 2025·European Journal of Nuclear Medicine and Molecular Imaging

Evaluating gray matter heterotopia with Florbetapir and Flortaucipir pet: a case report

Article

Author: Shu, Qiaoqiao ; Xu, Zhenchun ; Xiang, Xiaojiao ; Cai, Liang ; Feng, Yue

01 Sep 2025·Alzheimers & Dementia

Birth weight, incident dementia risk, and PET amyloid burden: The ARIC study

Article

Author: Emanuel, Olivia M. ; Egle, Marco ; Groechel, Renée C. ; Lee, Mark ; Sullivan, Kevin J. ; Wong, Dean F. ; Gottesman, Rebecca F. ; Lutsey, Pamela L. ; Schneider, Andrea L. C. ; Mosley, Thomas H.

Abstract:

INTRODUCTION:

The relationships among birth weight (BW), incident dementia, and amyloid beta (Aβ) are unknown.

METHODS:

Ten thousand four hundred seventy‐six Atherosclerosis Risk in Communities (ARIC) study participants without dementia reported their BW (1996–1998; low [< 5.5 lbs], medium [5.5–9.0 lbs], or high [> 9.0 lbs]), if premature (yes/no), and were followed for incident dementia (N dementia = 2550) through 2019. A subset (N = 312) had florbetapir positron emission tomography (2011–2014). BW was evaluated in association with dementia (Cox proportional hazards) and Aβ (logistic regression), adjusted for demographics, apolipoprotein E ε4, and vascular risk. Effect modification by race was explored.

RESULTS:

Neither low BW nor prematurity were associated with dementia. Dementia risk was elevated in Black (adjusted hazard ratio 1.95, 95% confidence interval 1.33, 2.86) but not White participants reporting high (versus medium) BW (P‐interaction = 0.001). BW was not associated with Aβ.

DISCUSSION:

Low BW was not associated with dementia or Aβ. High BW was associated with dementia in Black participants only. Further research should evaluate the role of BW in dementia etiology.

Highlights:

Low birth weight was not associated with an increased risk of incident dementia.The association between birth weight and incident dementia was modified by race.High birth weight was associated with dementia in Black adults.Odds of elevated standardized uptake value ratio was lower for those who were low birth weight.

01 Sep 2025·JAMA Neurology

Concordance Between Amyloid-PET Quantification and Real-World Visual Reads

Article

Author: Gatsonis, Constantine ; Soleimani-Meigooni, David N. ; Carrillo, Maria C. ; Schonhaut, Daniel R. ; Whitmer, Rachel A. ; Yadollahikhales, Golnaz ; Romanoff, Justin ; Hanna, Lucy ; Smith, Karen ; Iaccarino, Leonardo ; Apgar, Charles ; Koeppe, Robert A. ; Mundada, Nidhi S. ; Ranasinghe, Kamalini G. ; Cho, Hanna ; Rabinovici, Gil D. ; March, Andrew ; Windon, Charles ; Siegel, Barry A. ; Zeltzer, Ehud ; Blazhenets, Ganna ; Hillner, Bruce E. ; La Joie, Renaud

Importance:

With increased payer coverage and the advent of antiamyloid therapies, clinical use of amyloid positron emission tomography (PET) is likely to increase to help guide the diagnosis and treatment of patients with cognitive impairment. However, unlike most previous research studies, in clinical practice, scan acquisition is less standardized, interpretation typically relies purely on visual reads rather than scan quantification, and patients have more frequent comorbidities, all of which might compromise test accuracy.

Objective:

To compare visual interpretation of amyloid-PET in real-world clinical settings to scan interpretation based on central quantification, in order to assess the accuracy of clinical reads.

Design, Setting, and Participants:

This cross-sectional quality improvement study used data from the Imaging Dementia—Evidence for Amyloid Scanning study, collected between February 2016 and January 2018 and analyzed between December 2021 and April 2023. The setting included 294 imaging facilities in the US. Medicare beneficiaries 65 years or older with cognitive decline for whom Alzheimer disease was a diagnostic consideration were recruited by dementia specialists from their clinical practices.

Exposures:

Amyloid-PET with [18F]florbetapir, [18F]florbetaben, or [18F]flutemetamol.

Main Outcomes and Measures:

PET scans were visually interpreted as positive or negative by local radiologists or nuclear medicine physicians following approved guidelines. Independently, scans were centrally processed and quantified using the standardized Centiloid (CL) scale. We applied an a priori autopsy-based threshold of 24.4 CL to quantitatively define scan positivity.

Results:

Of 18 293 participants included in the parent study, scan images were available for 10 774 (59%), of which Centiloids were successfully calculated for 10 361 (96%). Median (IQR) patient age was 75 (71-80) years; 5245 patients (51%) were female, 6500 (63%) had mild cognitive impairment, and 3861 (37%) had dementia). Participants self-reported the following races and ethnicities: 1 Alaska Native (0%), 23 American Indian (0.2%), 188 Asian (1.8%), 316 Black (3.1%), 449 Hispanic or Latino (4.3%), 8 Native Hawaiian or Other Pacific Islander (0.1%), and 9125 White (88.2%). A total of 6332 scans (61%) were visually read as positive, and 6121 (59%) were quantitatively positive. Agreement between visual reads and quantitative classification was 86.3% (95% CI, 85.7%-87.0%; Cohen κ = 0.72; 95% CI, 0.70-0.73). A total of 5519 (53%) scans were positive visually and quantitatively (V+/Q+), 3416 (33%) were negative by both (V−/Q−), 813 (8%) were V+/Q−, and 602 (6%) were V−/Q+. Female sex (female: 4581/5241 [87.4%]; male: 4354/5109 [85.2%]; P =.001), White race (White race: 7900/9125 [86.6%]; non-White race: 1035/1225 [84.5%]; P =.046), and use of [18F]flutemetamol and [18F]florbetaben ([18F]flutemetamol: 559/628 [89.0%]; [18F]florbetaben: 2664/3032 [87.9%]; [18F]florbetapir: 5712/6690 [85.4%]; P &lt;.001), compared with [18F]florbetapir, were associated with higher visual-quantitative concordance. Scans within a 10- to 40-CL borderline positivity zone were more likely to be discordant.

Conclusions and Relevance:

This cross-sectional study found high concordance between local visual reads and central quantification of clinical amyloid-PET scans, supporting the validity of amyloid-PET visual reads in real-world clinical practice.

News (Medical) associated with Florbetapir F-18

07 Oct 2025

·www.fiercebiotech.com

Lilly calls for \'urgent improvements\' in Europe to boost diagnostic testing for Alzheimer\'s

Eli Lilly says Alzheimer\'s disease experts are warning the disease “remains critically underdiagnosed\" across Europe. \n Eli Lilly is calling on European countries to make “urgent improvements” to their Alzheimer’s disease diagnostic testing practices just weeks after nabbing a new approval on the continent for its Alzheimer\'s therapy Kisunla.The Indianapolis Big Pharma has teamed up with leading Alzheimer\'s experts at this year\'s Alzheimer Europe Conference to call for “urgent improvements to diagnostic pathways to ensure people in Europe can benefit from new therapeutic innovation.”Lilly points to a recent survey, published in the Journal of Alzheimer’s Disease, that found 70% of clinicians believe biomarker tests, which can find evidence of Alzheimer\'s or dementia, are “important or extremely important.\" Still, such tests remain \"underutilized,\" according to Lilly\'s Oct. 7 release.The survey questioned clinicians who treat patients with mild cognitive impairment (MCI) and Alzheimer\'s in France, Germany, Italy, Spain, the U.K., Japan and the U.S. The team found that across these countries, fewer than 1 in 5 patients (15.2%) received biomarker testing to confirm the specific pathology, with those in Germany and the U.K. the least likely to receive these tests, according to the journal.As a result, experts warn Alzheimer\'s and dementia “remain critically underdiagnosed,” Lilly said in the release, which has the effect of \"denying patients the opportunity to access treatment and care options.\"Lilly markets Kisunla, which works as an amyloid-plaque-targeting therapy and has an FDA approval for early symptomatic Alzheimer\'s, which includes the MCI or the mild dementia stages of the disease.The drug was approved by the FDA last year and received a final European sign-off just last month.To qualify for the drugs, patients must have a confirmed amyloid pathology, which can be done via several routes including a PET scan, a blood test or an MRI.Lilly also markets Amyvid, which works as an injectable prescription imaging agent to find high level of plaques. These are a buildup of a protein called amyloid beta in the brain that, if found, can be ultimately used by patients or their doctors to help prescribe Alzheimer\'s meds such as Kisunla. More diagnoses of Alzheimer\'s also mean potentially more uptake for medicines. Rival drug Leqembi, marketed by Biogen and Eisai, was also approved in the EU earlier this year.“Emerging therapies that target the pathology of Alzheimer\'s disease offer hope to slow progression and delay the need for care services,” said Stéphane Epelbaum, M.D., Ph.D., associate vice president for international medical affairs at Eli Lilly, in a statement.“But this possibility hinges on early detection, as approximately one-third of individuals in early symptomatic stages of the disease will progress to more advanced clinical stages within one year. Timely and accurate diagnosis is essential to ensure patients can access the next generation of Alzheimer\'s disease care.”

$Lilly calls for \'urgent improvements\' in Europe to boost diagnostic testing for Alzheimer\'s$

Drug Approval

30 Aug 2025

·www.prnewswire.com

FDA Approval of Leqembi Subcutaneous Formulation Charts Path to Combination Therapies for Alzheimer's Disease

Subcutaneous delivery increases accessibility and introduces potential for at-home administration, following model of diabetes and GLP-1 drugs NEW YORK, Aug. 29, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today announced its approval of a subcutaneous formulation of Leqembi (lecanemab), branded as Leqembi Iqlik, for weekly maintenance dosing following the 18-month IV initiation phase. This is a major advancement that opens the door for faster and simpler drug delivery and paves the way for combination therapies – the same strategy that revolutionized cancer care. "This shift to subcutaneous maintenance dosing is a crucial step toward making Leqembi more accessible for patients, similar to how diabetes and GLP-1 medications are delivered, and represents the first step towards the day when patients can bypass infusions altogether," said Dr. Howard Fillit, Co-Founder and Chief Science Officer at the ADDF. "This milestone lessens the burden on patients and caregivers by reducing the logistical challenges of receiving Alzheimer's treatment, while also bringing us closer to the day when patients can more easily receive a combination of drugs, potentially administered from home." Subcutaneous delivery means the drug can be injected just under the skin using an autoinjector once a week – taking only about 15 seconds – rather than requiring hour-long intravenous infusions in hospitals or infusion sites. While this administration method is currently only approved for maintenance dosing, Eisai and Biogen plan to file another application next week for subcutaneous dosing without the need for an IV initiation phase. As more Alzheimer's treatments progress through development and gain approval, subcutaneous formulations will likely become increasingly common. Beyond convenience, this delivery innovation removes a critical barrier to combination therapies. With a more practical and scalable approach to drug administration, physicians will be better positioned to incorporate additional therapies that target the full spectrum of aging biology. This is especially timely as more than 70% of the current Alzheimer's drug pipeline focuses on non-amyloid pathways. "We've long known that Alzheimer's is not a one-target disease, and the future lies in precision combination therapies tailored to each patient based on their individual biomarker profiles," Dr. Fillit said. "Subcutaneous delivery is more than an upgrade – it's a gateway to the next generation of Alzheimer's care, accelerating our ability to bring effective, multi-modal treatment regimens to the millions of patients who need them." About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the development of drugs to prevent, treat, and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug development, biomarker, and prevention programs in 21 countries. To learn more, please visit: . SOURCE Alzheimer's Drug Discovery Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

28 Jul 2025

·www.prnewswire.com

Next Era of Alzheimer's Care Will be Defined by Precision Prevention

New U.S. study reflects growing role of lifestyle interventions, further highlighting need to study lifestyle and drugs in combination NEW YORK, July 28, 2025 /PRNewswire/ -- Results from the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) released today strengthen the case for precision prevention, a strategy set to revolutionize Alzheimer's care by combining lifestyle changes with targeted therapeutics based on individual risk factors. "The future lies in precision prevention," said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the Alzheimer's Drug Discovery Foundation. "We have seen this model succeed in cancer and heart disease, and with a growing body of evidence showing neither lifestyle nor drugs can stop Alzheimer's alone, now is the time to double down on studying the two in combination, which will lay the path for precision medicine." The ADDF is driving a new era of clinical trials that look at lifestyle and therapeutic interventions in tandem, including Dr. Miia Kivipelto's MET-FINGER study, which has created a blueprint for combination therapy studies going forward. The U.S. POINTER study, released during the Alzheimer's Association International Conference (AAIC) and published simultaneously in the Journal of the American Medical Association (JAMA), found multidomain lifestyle interventions supported cognitive health in aging populations. This builds on previous findings from Dr. Miia Kivipelto's original FINGER trial, the first to show the critical role of lifestyle changes in preventing dementia. U.S. POINTER showed its structured high-intensity lifestyle interventions benefitted participants regardless of their APOE4 carrier status, a genetic risk factor for Alzheimer's disease. This contrasts findings from the FINGER study, which showed benefit especially in carriers of APOE4, and further highlights the wide-reaching impacts of lifestyle changes. "The U.S. POINTER results validate the findings of the FINGER study in a more diverse U.S. population," said Dr. Kivipelto. "This is yet another proof point that lifestyle can have a tremendous impact on the brain. By developing personalized scientific approaches to match each patient's unique biomarker profile with a combined drug and prevention plan, we are redefining how we treat and prevent Alzheimer's." About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the development of drugs to prevent, treat, and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug development, biomarker, and prevention programs in 21 countries. To learn more, please visit: . SOURCE Alzheimer's Drug Discovery Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Study

100 Deals associated with Florbetapir F-18

External Link

KEGG	Wiki	ATC	Drug Bank
D09617	Florbetapir F-18	V09AX05	DB09149

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Alzheimer Disease	European Union	Eli Lilly Nederland BV	14 Jan 2013
Alzheimer Disease	Iceland	Eli Lilly Nederland BV	14 Jan 2013
Alzheimer Disease	Liechtenstein	Eli Lilly Nederland BV	14 Jan 2013
Alzheimer Disease	Norway	Eli Lilly Nederland BV	14 Jan 2013
Contrast agents	United States	Avid Radiopharmaceuticals, Inc.	06 Apr 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dementia due to Alzheimer's disease (disorder)	Phase 3	China	JYAMS PET Research & Development Ltd.	20 Oct 2022
Cognitive Dysfunction	Phase 3	United States	Avid Radiopharmaceuticals, Inc.	01 Jul 2011
Mild cognitive disorder	Phase 3	-	Avid Radiopharmaceuticals, Inc.	01 Feb 2011
Chronic Traumatic Encephalopathy	Phase 2	United States	Avid Radiopharmaceuticals, Inc.	01 Jun 2014
Lewy Body Disease	Phase 2	United States	Avid Radiopharmaceuticals, Inc.	01 Mar 2010
Striatonigral Degeneration	Phase 2	United States	Avid Radiopharmaceuticals, Inc.	01 Mar 2010
Frontotemporal Dementia	Phase 2	United Kingdom	Avid Radiopharmaceuticals, Inc.	01 Sep 2009
Parkinson Disease	Phase 2	United States	Avid Radiopharmaceuticals, Inc.	01 Jan 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04118764 (CTgov)	Not Applicable	Alzheimer Disease	6	Neuronavigation-guided single-element focused ultrasound transducer+Amyvid+Definity	ccfbzilmkf = rxnunrklcm ddubycvlct (nqvukwrcpn, rswamtiiuo - rmyeyjowqc) View more	-	26 Aug 2024
NCT01683825 (CTgov)	Phase 4	Senile cardiac amyloidosis	23	florbetapir	zlvyepoqmr(vobfwdxlpv) = xenfwnysco xyyqcwolzq (wxwydxixsz, kayeangitf - rgosbswnek) View more	-	13 Apr 2022
NCT01767493 (CTgov)	Phase 4	Multiple Sclerosis, Relapsing-Remitting	19	[18F]Florbetapir PET imaging	glaezyqdlm = xjlkbxbrqy difusjozmv (dbjahkdjqc, lfdtuviavu - rtsavuhchk) View more	-	27 Aug 2021
NCT01518374 (CTgov)	Phase 2	Alzheimer Disease \| Mild cognitive disorder	1,768	Florbetapir F 18	rguvwjjllr = ckbqlvpccl tophzmduce (jtqxiuihwx, iemqzipnqu - xwwiazxerf) View more	-	14 Jun 2018
NCT02051790 (CTgov)	Phase 4	Alzheimer Disease	241	florbetapir F 18	bzlbinjtur = xcakwtnpek bvqhydpbge (qerisvyqlm, igrixiyulp - aeqyggmfcp) View more	-	28 Sep 2015
NCT01890343 (CTgov)	Phase 2	Alzheimer Disease \| Frontotemporal Dementia	34	florbetapir 18F+18F-FDG (Frontotemporal Disorder)	bnfrwpfzow = amtldtjmcw ddqcrqssts (dukixaluvo, foqphzmusb - eqhhrbqmjo) View more	-	17 Sep 2014
NCT01890343 (CTgov)	Phase 2	Alzheimer Disease \| Frontotemporal Dementia	34	florbetapir 18F (Cognitively Normal)	bnfrwpfzow = wzdmqzpewm ddqcrqssts (dukixaluvo, auneepqcmz - mjbmliccuc) View more	-	17 Sep 2014
NCT01662882 (CTgov)	Phase 2/3	Alzheimer Disease \| Mild cognitive disorder	48	florbetapir (18F) (AD Subjects)	sogqozdqwb = qdlhvjzcqv ryywpnmoah (asgtmeqzaz, elmofdsafj - ufmvoqvagq) View more	-	19 Sep 2013
NCT01662882 (CTgov)	Phase 2/3	Alzheimer Disease \| Mild cognitive disorder	48	florbetapir (18F) (Healthy Controls)	sogqozdqwb = ueijxcmreh ryywpnmoah (asgtmeqzaz, xywxmcwkth - bghawinhjj) View more	-	19 Sep 2013
NCT01447719 (Pubmed \| Lancet Neurol)	Phase 3	Plaque, Amyloid	59	Florbetapir PET imaging	icbiefuxfu(sngixcgyky) = kyowtbarbe rsqdkbnlob (emaesatpao, 78 - 98) View more	-	01 Aug 2012
NCT01447719 (Pubmed \| Lancet Neurol)	Phase 3	Plaque, Amyloid	59	florbetapir (Autopsy)	icbiefuxfu(sngixcgyky) = tpzlggxjqt rsqdkbnlob (emaesatpao, 80 - 100) View more	-	01 Aug 2012
NCT01565382 (CTgov)	Phase 3	Alzheimer Disease \| Mild cognitive disorder	40	Florbetapir	omabpzwvdt = wnfefpnvry vxtioauqlk (hicuumofhw, aihehqrkht - iiccpjjizf) View more	-	27 Jun 2012
NCT00857415 (CTgov)	Phase 3	Alzheimer Disease	226	florbetapir F 18 (Autopsy Cohort)	ogeichkwhv = qhagzgufsf lyysynpzpm (zflmorbxfe, fictxfsxmm - glybdafptg) View more	-	07 May 2012
NCT00857415 (CTgov)	Phase 3	Alzheimer Disease	226	florbetapir F 18 (Specificity Cohort)	jzgzmqruyz = ucoxaivbub ywstqcibqa (ojrhfsajme, infpmnbkdi - jcgcpodxek) View more	-	07 May 2012

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Florbetapir F-18

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation